Akhmed Kh, Agababian I R, Mareev V Iu, Sazonova L N, Ataullakhanova D M
Ter Arkh. 1986;58(11):58-61.
A total of 18 patients with chronic congestive heart failure were examined using an acute pharmacological test (25-50 mg of captopril) and during 2-week course treatment. A marked positive effect of the drug was noted in 15 (83.3%) patients. Captopril significantly decreased venous tone by 19.0 +/- 2.4% and by 40.4 +/- 4.1% and regional vascular resistance by 25.7 +/- 1.9% and by 39.4 +/- 2.9% in the acute test and in course treatment, respectively. Microcirculatory indices also improved: there was an increase in tissue oxygenation (PO2 by 38.8 +/- 2.7%), oxygen supply rate and small arteriolar function (more pronounced in course treatment). Platelet aggregation in the captopril acute test was slightly decreased but in course treatment it did not significantly differ from the initial one. A conclusion was made that captopril, mostly in course treatment, decreased venular and arteriolar tone and improved microcirculatory processes making an insignificant effect on platelet aggregation permitting its recommendation for prolonged treatment of patients with chronic congestive heart failure with minimum risk of complications.
共有18例慢性充血性心力衰竭患者接受了急性药理学试验（25 - 50毫克卡托普利）检查，并在为期2周的疗程中接受治疗。15例（83.3%）患者出现了该药物明显的积极效果。在急性试验和疗程治疗中，卡托普利分别使静脉张力显著降低19.0±2.4%和40.4±4.1%，使局部血管阻力分别降低25.7±1.9%和39.4±2.9%。微循环指标也有所改善：组织氧合增加（氧分压增加38.8±2.7%）、氧供应率和小动脉功能增强（疗程治疗中更明显）。卡托普利急性试验中血小板聚集略有下降，但疗程治疗中与初始值无显著差异。得出的结论是，卡托普利主要在疗程治疗中降低了小静脉和小动脉张力，改善了微循环过程，对血小板聚集影响不大，因此推荐用于慢性充血性心力衰竭患者的长期治疗，并发症风险最低。
